Severe thrombocytopenia related to long-term trastuzumab exposure

Elena Aguirre¹, Teresa Taberner¹, Armando Luaña², Serafin Morales¹, and Antonio Llombart¹

¹Department of Oncology, and ²Department of Hematology, Hospital Arnau de Vilanova, Lérida, Spain

ABSTRACT

Drug-induced immune thrombocytopenia may occur secondary to several chemotherapeutic agents or new targeted monoclonal antibodies, but thrombocytopenia induced by trastuzumab is a very rare occurrence. We report a case of severe thrombocytopenia related to the administration of trastuzumab six months after the first exposure.

Key words: thrombocytopenia, trastuzumab, breast cancer.

Conflicts of interest: None declared.

Financial disclosures: None declared.

Correspondence to: Elena Aguirre Ortega, Servicio de Oncologia Médica, Hospital Arnau de Vilanova, Avenida Rovira Roure 80, 25001 Lérida, Spain. Tel +34-629-842661; email elenaaguirreortega@yahoo.es

Received September 7, 2011; accepted October 15, 2012.